I just got back from a visit to City of Hope, and it turns out I have no choices to make after all. My prostate cancer makes me ineligible for clinical trials, so my best option is an FDA-approved bispecific treatment called Talvey, or talquetamab:
TALVEY™ is a bispecific T-cell engaging antibody that binds to the CD3 receptor on the surface of T cells and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on the surface of multiple myeloma cells, non-malignant plasma cells and healthy tissue such as epithelial cells in keratinized tissues of the skin and tongue.¹
There you have it. Unlike my previous CAR-T treatment, which targeted the BCMA antigen on the surface of cancerous cells, talquetamab targets GPRC5D. So it's a whole new thing for my body.
I now have three separate opinions that talquetamab is probably my best choice at the moment, so that's what I'll do. Sadly, the CoH doctor indicated that it requires dexamethasone to work properly, so I'll be back on the Evil Dex. This should all start up in a few weeks.
¹The mention of "tongue" here is a veiled reference to the fact that it kills tongue cells and is therefore also likely to kill my sense of taste to some extent. Hooray.